Skip to content
Screener

BridgeBio Pharma BBIO Cash Flow Statement

Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
-$155.89M+15.2%-$166.56M+1.8%-$194.64M+27.2%-$184.94M-12.6%-$183.76M-143%
$1.05M-20.0%$1.19M-7.6%$1.44M+5.0%$1.4M-9.1%$1.32M-16.3%
$44.07M+18.3%$33.24M+28.4%$34.64M+15.0%$35.26M+29.8%$37.24M+73.6%
-$71.1M+11.9%-$197.28M+1.0%-$56.42M+71.1%-$109.57M+39.3%-$80.68M—
$443K-25.4%$69K—$33K-29.8%$470K+243%$594K+1,000%
——-$42.74M-2,579%-$14.35M———-$13M-528%
$127.5M—$82.5M+70.9%——————
——————————
$0—$0-100%——————
——$549.89M+812%————$302.04M—
——$309.88M+321%-$72.96M-126%-$106M—$208.36M+189%
-$71.54M+12.0%-$197.35M+0.9%-$56.45M+71.1%-$110.04M+39.1%-$81.28M—

FAQ

How much cash does BridgeBio Pharma generate?
BridgeBio Pharma (BBIO) generated -$434.4M in operating cash flow over the trailing twelve months.
What is BridgeBio Pharma's free cash flow?
After $1.0M of capital expenditures, BridgeBio Pharma's free cash flow was -$435.4M over the trailing twelve months, up 33.7% year over year.
Where does BridgeBio Pharma's cash flow data come from?
Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.